Anti-EGFRvIII mutation Antibody, clone L8A4

Epidermal growth factor receptor (UniProt: P00533; also known as EC:2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1) is encoded by the EGFR (also known as ERBB, ERBB1, HER1) gene (Gene ID: 1956) in human. EGFR is a single-pass type 1 membrane protein that is ubiquitously expressed. It is synthesized with a 24 amino acids signal peptide that is subsequently cleaved. It contains an extracellular domain (aa 25-645) a transmembrane domain (aa 646-668), and a cytoplasmic domain (aa 669-1210). Upon binding of EGF, the receptor is phosphorylated and recruits adapter proteins to turn on downstream signaling cascades. EGFR is commonly overexpressed and is mutated in many human malignancies and is often associated with aggressive phenotypes. The most common truncated EGFR is the variant III EGFR deletion mutant (EGFRvIII), containing an inframe deletion of exons 2 7 (801 bp) from the extracellular domain. EGFRvIII mutation is reported in about 5% of human lung squamous cell carcinoma (SCC). It has also been suggested that EGFRvIII potentially plays an essential role in the human NSCLC tumor initiation and maintenance. Drugs such as Gefitinib, erlotnib, and HKI-272 are shown to inhibit the growth of EGFRvIII transformed cells and tumor growth. This monoclonal antibody binds specifically to the epidermal growth factor receptor variant III (EGFRvIII), which is present on gliomas, but not normal tissues, and is internalized rapidly after receptor binding. (Ref.: Ji, H., et al. (2006). Proc. Natl. Acad. Sci. USA 103(20); 7817-7822; Hens, M., et al. (2010). Nucl. Med. Biol. 37(7); 741-750).

Clone L8A4 specifically binds to EGFRvIII, a mutated form of EGFR.

KLH-conjugated linear peptide corresponding to the predicted amino acid sequence of 14 amino acids at the fusion junction combined with cultured HC2 20 d2 cells.

Anti-EGFRvIII mutation, clone L8A4, Cat. No. MABC1126, is a mouse monoclonal antibody that detects Epidermal Growth Factor Receptor variant III and has been tested for use in ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Research Category
Apoptosis & Cancer

Western Blotting Analysis: A representative lot detected EGFRvIII mutation in Western Blotting applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Grandi, P., et. al. (2010). Cancer Gene Ther. 17(9):655-63; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

Immunohistochemistry (Paraffin) Analysis: A representative lot detected EGFRvIII mutation in Immunohistochemistry applications (Mellinghoff, I.K., et. al. (2005). N Engl J Med. 353(19):2012-24; Sok, J.C., et. al. (2006). Clin Cancer Res. 12(17):5064-73).

Immunohistochemistry Analysis: A representative lot detected EGFRvIII mutation in Immunohistochemistry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

ELISA Analysis: A representative lot detected EGFRvIII mutation in ELISA applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

Flow Cytometry Analysis: A representative lot detected EGFRvIII mutation in Flow Cytometry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

Immunocytochemistry Analysis: A representative lot detected EGFRvIII mutation in Immunocytochemistry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Batra, S.K., et. al. (1995). Cell Growth Differ. 6(10):1251-9).

Evaluated by Western Blotting in NR6 cells expressing human EGFRvIII (NR6M).

Western Blotting Analysis: 1 µg/mL of this antibody detected EGFRvIII mutation in NR6 cells expressing human EGFRvIII (NR6M).

~145 kDa observed. Uncharacterized bands may be observed in some lysate(s).

Format: Purified

Protein G purified

Purified mouse monoclonal antibody IgG1 in PBS without azide.

Stable for 1 year at -20°C from date of receipt.

Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.